A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy

• Published in: PloS one 2012-10, Vol.7 (10), p.e40388
• Main Authors: Chao, Xu, Zhang, Zhuoli, Guo, Lili, Zhu, Jingjing, Peng, Mingli, Vermorken, Alphonsus J M, Van de Ven, Wim J M, Chen, Chao, Cui, Yali
• Format: Article
• Language: English
• Subjects: Animal tissues; Animals; Anthracyclines; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - chemistry; Antibiotics, Antineoplastic - toxicity; Anticancer properties; Antitumor activity; Biocompatibility; Cancer; Cancer therapies; Cell Survival - drug effects; Chemotherapy; Cytotoxicity; Dose-Response Relationship, Drug; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - pharmacokinetics; Doxorubicin - toxicity; Drug Carriers; Drug delivery; Drug delivery systems; Drug Delivery Systems - methods; Drug development; Drug dosages; Drug therapy; Drugs; Electromagnetic fields; Engineering research; Gold - chemistry; Health aspects; Hepatoma; In vivo methods and tests; Intravenous administration; Laboratory animals; Life sciences; Life span; Liver cancer; Liver Neoplasms, Experimental - drug therapy; Liver Neoplasms, Experimental - pathology; Low frequency; Magnetic fields; Magnetics; Materials Science; Medicine; Metal Nanoparticles - administration & dosage; Metal Nanoparticles - chemistry; Metal Nanoparticles - toxicity; Mice; Nanoparticles; Oncology; Optimization; Organs; Polyethylene glycol; Polyethylene Glycols - chemistry; Polymers; Safety engineering; Side effects; Studies; Survival Analysis; Tissue Distribution; Toxicity; Tumor Burden - drug effects; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0040388

Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p